GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
ATHENAHEALTH INC (ATHN) [hlAlert]

Rating:
Outperform
ATHN
up 3.23 %

ATHENAHEALTH INC (ATHN) upgraded to Outperform by Leerink Swann

Posted on: Friday,  Dec 13, 2013  8:25 AM ET by Leerink Swann

Leerink Swann rated Outperform ATHENAHEALTH INC (NASDAQ: ATHN) on 12/13/2013, when the stock price was $130.34. Since
then, ATHENAHEALTH INC has gained 3.24% as of 11/17/2015's recent price of $134.56.
If you would have followed this Leerink Swann 's recommendation on ATHN, you would have gained 3.23% of your investment in 704 days.

athenahealth, Inc. (athena) is a provider of Internet-based business services for physician practices. The Company's service offerings are based on four integrated components: its Internet-based software, its continually updated database of payer reimbursement process rules, its back-office service operations that perform administrative aspects of billing and clinical data management for physician practices, and its automated and live patient communication services. The Company?s principal offering, athenaCollector, automates and manages billing-related functions for physician practices and includes a medical practice management platform. The Company has also developed a service offering, athenaClinicals that automates and manages medical record-related functions for physician practices and includes an electronic medical record (EMR) platform. In October 2009, the Company completed the acquisition of Anodyne Health Partners, Inc.

Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions. Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann to provide growth-focused clients an expertise earned through experience.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/13/2013 8:25 AM Buy
None
130.34
as of 12/13/2013
1 Week   
1 Month   
3 Months down  -1.92 %
1 YTD up  51.16 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/24/2013 8:25 AM Hold
None
110.79
12/7/2012 9:25 AM Buy
None
73.18
6/25/2009 8:25 AM Buy
None
34.15
1/6/2009 8:25 AM Hold
None
33.00
12/3/2008 8:25 AM Buy
None
24.60 34.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy